Evidence map›Paper›PMID 36153659›Full record

ArticleEmerging microbes & infections2022

Pathogen-host adhesion between SARS-CoV-2 spike proteins from different variants and human ACE2 studied at single-molecule and single-cell levels.

Xiaoxu Zhang, Bixia Hong, Peng Wei, Pengfei Pei, Haifeng Xu, Long Chen, Yigang Tong, Jialin Chen, Shi-Zhong Luo, Huahao Fan and 1 more

Open access · goldAbstract read
In one paragraph

Article in Emerging microbes & infections, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Xiaoxu ZhangBeijing Advanced Innovation Center for Soft Matter Science and Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, People's Republic of China.ORCID 0000-0003-2724-9896
Bixia HongBeijing Advanced Innovation Center for Soft Matter Science and Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, People's Republic of China.
Peng WeiSchool of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, People's Republic of China.ORCID 0000-0002-3721-7014
Pengfei PeiBeijing Advanced Innovation Center for Soft Matter Science and Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, People's Republic of China.
Haifeng XuBeijing Laboratory of Biomedical Materials, College of Materials Science and Engineering, Beijing University of Chemical Technology, Beijing, People's Republic of China.
Long ChenBeijing Advanced Innovation Center for Soft Matter Science and Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, People's Republic of China.ORCID 0000-0002-3812-1815
Yigang TongBeijing Advanced Innovation Center for Soft Matter Science and Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, People's Republic of China.ORCID 0000-0002-8503-8045
Jialin ChenState Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, People's Republic of China.ORCID 0000-0001-6294-876X
Shi-Zhong LuoBeijing Advanced Innovation Center for Soft Matter Science and Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, People's Republic of China.ORCID 0000-0002-4880-5962
Huahao FanBeijing Advanced Innovation Center for Soft Matter Science and Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, People's Republic of China.ORCID 0000-0001-5007-2158
Chengzhi HeBeijing Advanced Innovation Center for Soft Matter Science and Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, People's Republic of China.ORCID 0000-0001-5013-0207
Beijing University of Chemical Technology · CNBeijing University of Chinese Medicine · CNGuiyang Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The binding of the receptor binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein onto human angiotensin-converting enzyme 2 (ACE2) is considered as the first step for the virus to adhere onto the host cells during the infection. Here, we investigated the adhesion of spike proteins from different variants and ACE2 using single-molecule and single-cell force spectroscopy. We found that the unbinding force and binding probability of the spike protein from Delta variant to the ACE2 were the highest among the variants tested in our study at both single-molecule and single-cell levels. As the most popular variants, the Omicron variants have slightly higher unbinding force to the ACE2 than wild type. Molecular dynamics simulation showed that ACE2-RBD (Omicron BA.1) complex is destabilized by the E484A and Y505H mutations and stabilized by S477N and N501Y mutations, when compared with Delta variant. In addition, a neutralizing antibody, produced by immunization with wild type spike protein, could effectively inhibit the binding of spike proteins from wild type, Delta and Omicron variants (BA.1 and BA.5) onto ACE2. Our results provide new insight for the molecular mechanism of the adhesive interactions between spike protein and ACE2 and suggest that effective monoclonal antibody can be prepared using wild type spike protein against different variants.

Indexed as

COVID-19Spike Glycoprotein, CoronavirusAngiotensin-Converting Enzyme 2HumansMutationPeptidyl-Dipeptidase AProtein BindingSARS-CoV-2Angiotensin-Converting Enzyme 2Peptidyl-Dipeptidase ASpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2force spectroscopyneutralizing antibodypathogen-host adhesionSARS-CoV-2

Identifiers

PMID36153659
PMCPMC9639500
OpenAlexW4297200872

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.